JPS63156719A - Syrup - Google Patents
SyrupInfo
- Publication number
- JPS63156719A JPS63156719A JP30346286A JP30346286A JPS63156719A JP S63156719 A JPS63156719 A JP S63156719A JP 30346286 A JP30346286 A JP 30346286A JP 30346286 A JP30346286 A JP 30346286A JP S63156719 A JPS63156719 A JP S63156719A
- Authority
- JP
- Japan
- Prior art keywords
- syrup
- carbocystine
- carbocysteine
- added
- sugar alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000020357 syrup Nutrition 0.000 title claims abstract description 29
- 239000006188 syrup Substances 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 12
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 12
- 229960002920 sorbitol Drugs 0.000 claims abstract description 12
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 claims abstract description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960004399 carbocisteine Drugs 0.000 claims abstract description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 8
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 8
- 239000004334 sorbic acid Substances 0.000 claims abstract description 8
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 8
- 239000000811 xylitol Substances 0.000 claims abstract description 8
- 235000010447 xylitol Nutrition 0.000 claims abstract description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 8
- 229960002675 xylitol Drugs 0.000 claims abstract description 8
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000013736 caramel Nutrition 0.000 claims abstract description 7
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 239000000796 flavoring agent Substances 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- 239000003381 stabilizer Substances 0.000 claims abstract description 5
- 239000003086 colorant Substances 0.000 claims abstract description 4
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims abstract description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003002 pH adjusting agent Substances 0.000 claims abstract description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 4
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 4
- 229940085605 saccharin sodium Drugs 0.000 claims description 4
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 10
- 239000000243 solution Substances 0.000 abstract description 9
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 abstract description 7
- 238000000354 decomposition reaction Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 206010036790 Productive cough Diseases 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 208000023504 respiratory system disease Diseases 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 235000003599 food sweetener Nutrition 0.000 description 15
- 239000003765 sweetening agent Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008213 purified water Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 239000000686 essence Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000004040 coloring Methods 0.000 description 3
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PBILBHLAPJTJOT-CQSZACIVSA-N Phyllodulcin Chemical compound C1=C(O)C(OC)=CC=C1[C@@H]1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-CQSZACIVSA-N 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PBILBHLAPJTJOT-UHFFFAOYSA-N 3S-phyllodulcin Natural products C1=C(O)C(OC)=CC=C1C1OC(=O)C2=C(O)C=CC=C2C1 PBILBHLAPJTJOT-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- -1 glycyrrhizic acid disodium salt Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野］
本発明は、カルボシスティンを含む安定なシロップ剤の
処方及び製造方法に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a method for formulating and producing a stable syrup containing carbocystine.
カルボシスティンは次の構造式
）１００ｃｃＨ２ｓｃｌ（２−Ｃ−ＣＯＯＨＮＨ２
で示される化合物の一般名であり、気道粘液に含まれる
各種ムチンの含量比を正常化することにより、痰の粘度
を低下させる気道粘液調整・粘膜正常化剤である。臨床
的には各種呼吸器疾患の去痰に優れた効果が認められ、
錠剤及びシロップ剤としてムコダイン（登録商標）の商
品名ので製品化されている。Carbocystine is the general name of a compound represented by the following structural formula) 100ccH2scl (2-C-COOHNH2), and is an airway mucus that lowers the viscosity of sputum by normalizing the content ratio of various mucins contained in airway mucus. It is a regulating and mucous membrane normalizing agent.Clinically, it has been recognized to have excellent effects on expectoration in various respiratory diseases.
It is commercialized as tablets and syrup under the trade name Mucodyne (registered trademark).
［従来の技術とその問題点］
シロップ剤に添加される甘味剤は一般にショ糖及びブド
ウ糖が用いられている。しかし、カルボシスティンのシ
ロップ剤にこのような還元糖を用いると、アミノ酸であ
るカルボシスティンとメイラード反応を起こし、溶液が
褐変することが知られている。また、これらの糖の添加
により経時的なｐＨの低下がみられ、これもカルボシス
ティンの安定性を低下する欠点を有していた。[Prior art and its problems] Sucrose and glucose are generally used as sweeteners added to syrups. However, it is known that when such reducing sugars are used in carbocystine syrups, a Maillard reaction occurs with the amino acid carbocystine, causing the solution to turn brown. Furthermore, the addition of these sugars caused a decrease in pH over time, which also had the disadvantage of decreasing the stability of carbocystine.
カルボシスティンはｐＨによりその安定性が異なり、酸
性及びアルカル性側では分解がみられる。その分解物の
主なものは、３−チオモルポリノン−５−カルボン酸、
チオグリコール酸及びアラニンが生じる。このため、安
定な一定ｐＨを長期にわたって保持することか必須とな
る。The stability of carbocystine varies depending on the pH, and decomposition is observed in acidic and alkaline conditions. The main decomposition products are 3-thiomolporinone-5-carboxylic acid,
Thioglycolic acid and alanine are produced. Therefore, it is essential to maintain a stable constant pH over a long period of time.
カルボシスティンは独特の強い酸味を有し、シロップ剤
として服用する場合には矯味剤又は甘味剤を添加するこ
とが必須となるため、上記の問題を考慮してカルボシス
ティンと配合しても変化しない安定な矯味剤又は甘味剤
が求められていた。Carbocystine has a unique strong sour taste, and when taken as a syrup, it is essential to add a flavoring agent or sweetener, so taking the above problems into consideration, there is no change even if it is combined with carbocystine. There was a need for a stable flavoring or sweetening agent.
［発明が解決しようとする問題点］
この発明は、カルボシスティンのシロップ剤を製する場
合、その溶液の褐色変化を抑え、分解物の生成を抑制し
た安定な製剤とすると共に、服用しやすいシロップ剤の
処方成分を得ることを目的とする。[Problems to be Solved by the Invention] When producing a syrup of carbocystine, the present invention suppresses the browning of the solution, suppresses the production of decomposition products, and produces a stable preparation, as well as a syrup that is easy to take. The purpose is to obtain prescription ingredients for drugs.
［問題を解決するための手段及び作用コ以上の問題点を
解決せんがため、矯味剤としての甘味剤を研究し、着色
防止剤及び安定剤を鋭意研究し、本発明を完成させた。[Means and effects for solving the problem] In order to solve the above-mentioned problems, we researched sweeteners as flavoring agents, as well as coloring inhibitors and stabilizers, and completed the present invention.
一般的に甘味剤としては、天然甘味剤であるショ糖、ブ
ドウ糖、果糖、麦芽糖、キシロース、カエデ糖、蜂蜜、
パラチノース、カップリングシュガー及びネオシュガー
などが知られ、また糖アルコールでは、Ｄ−ソルビトー
ル、マンニトール、マルチトール、キシリトール、パラ
チノース及びリカシンなどが知られている。Common sweeteners include natural sweeteners such as sucrose, glucose, fructose, maltose, xylose, maple sugar, honey,
Palatinose, coupling sugar, neosugar, etc. are known, and among sugar alcohols, D-sorbitol, mannitol, maltitol, xylitol, palatinose, lycasin, etc. are known.
配糖体とその誘導体のグリチルリチン、グリチルリチン
酸二ナトリウム塩、グリチルリチン酸三ナトリウム塩、
ステビオサイド、α−Ｇスィート（α−グリコジルステ
ビオサイド）、レバウディアナサイド、フィロズルシン
及びローハンクオ等も知られている。アミノ酸及びペプ
チドとしてアスパルテーム（α−Ｌ−アスバチルーＬ−
フェニルアラニンメチルエステル）、グリシンが添加さ
れ、更にタンパク質甘味料としては、トウマチン、人工
合成甘味料として、サッカリンナトリウム、アスパルテ
−ムに１サイクロデキストリン等も公知である。Glycyrrhizin, glycyrrhizic acid disodium salt, glycyrrhizic acid trisodium salt of glycosides and its derivatives,
Also known are stevioside, α-G sweet (α-glycodyl stevioside), rebaudianaside, phyllodulcin, and lohankuo. Aspartame (α-L-asbatyl-L-
Phenylalanine methyl ester), glycine are added, and protein sweeteners such as toumatin, artificially synthesized sweeteners such as saccharin sodium, aspartame and monocyclodextrin are also known.
本発明者等は、以上の各種甘味剤をカルボシスティンに
配合した場合の安定性を調べた。The present inventors investigated the stability when the various sweeteners mentioned above were blended with carbocystine.
安定性試験は、５Ｗ／Ｖ％のカルボシスティンの水溶液
（ｐＨ６，５）に各種甘味剤を０．２〜４０Ｗ／Ｖ％添
加し、５０°、 ３０日間保存したときのｐ）Ｉ、着色
度（色差計を用いて測定した黄色度）及びカルボシステ
ィン残存率を測定して行なった。その結果を表１に示し
た。In the stability test, 0.2 to 40 W/V% of various sweeteners were added to a 5W/V% aqueous solution of carbocystine (pH 6,5), and the mixture was stored at 50° for 30 days to determine p)I and degree of coloration. (yellowness measured using a color difference meter) and carbocystine residual rate. The results are shown in Table 1.
表１ 、 ｓｗ／ｖ＊ カルボシスティンシロップの安
定性（５０°、３０日）
・ｐｌ＋及び着色度の値はいずれも開始時に対する変化
量を示す。Table 1, sw/v* Stability of Carbocystine Syrup (50°, 30 days) - The values of pl+ and degree of coloration both indicate the amount of change from the starting point.
・ｐＨの−は酸性側に、＋はアルカリ性側に変化したこ
とを示す。- pH indicates that the pH has changed to the acidic side, and + indicates that the pH has changed to the alkaline side.
・残存率は開始時に対するカルボシスティンの残存率を
示す。・Residual rate indicates the residual rate of carbocystine compared to the starting time.
この結果、安定性の高い甘味剤はＤ−ソルビトール、Ｄ
−マンニトール、キシリトール、及びサッカリンナトリ
ウムであり、特に服用時の下痢等の副次的症状を考慮す
れば経口甘味剤として最も適するのは、Ｄ−ソルビトー
ル又は、キシリトールであった。またこれらにサッカリ
ンナトリウムを加える等、２種以上の甘味剤を混和して
用いることもできる。As a result, the most stable sweeteners are D-sorbitol, D
- Mannitol, xylitol, and saccharin sodium, and D-sorbitol or xylitol was the most suitable as an oral sweetener, especially considering the secondary symptoms such as diarrhea during administration. It is also possible to use a mixture of two or more sweeteners, such as adding saccharin sodium to these sweeteners.
次に上記Ｄ−ソルビトール又はキシリトールのシロップ
剤への添加量とｐＨ１着色度及びカルボシスティン残存
率との関係を調べた。その結果を表２に示した。Next, the relationship between the amount of D-sorbitol or xylitol added to the syrup, the degree of coloration at pH 1, and the residual rate of carbocystine was investigated. The results are shown in Table 2.
表２、甘味剤の添加率と安定性（５０°、３０日）・ｐ
ｌ＋及び着色度の値はいずれも開始時に対する変化量を
示す。Table 2. Addition rate and stability of sweetener (50°, 30 days)・p
Both l+ and coloring degree values indicate the amount of change from the starting point.
・残存率は開始時に対するカルボシスティンの残存率を
示す。・Residual rate indicates the residual rate of carbocystine compared to the starting time.
以上の結果から、Ｄ−ソルビトール及びキシリトールに
ついて１０％以上の添加ではいずれもｐ）Ｉ、着色度及
び残存率に変化はみられなかった。甘味が最も良く、ま
た、使用上量も適した濃度は４０Ｗ／Ｖ ％であフた。From the above results, no change was observed in p)I, degree of coloring, and residual rate when D-sorbitol and xylitol were added in an amount of 10% or more. The concentration with the best sweetness and suitable amount for use was 40 W/V%.
またカルボシスティン水溶液は、そのｐＨにより安定性
が異なる。４ＤＶｌ／Ｖ ％Ｄ−ソルビトールを含む
５Ｗ／Ｖ ％カルボシスティンシロップ剤のｐ）Ｉに
対する安定性を調べた。その結果を表３に示した。Further, the stability of the carbocystine aqueous solution differs depending on its pH. The stability of a 5W/V% carbocystine syrup containing 4DVl/V% D-sorbitol against p)I was investigated. The results are shown in Table 3.
表３．５Ｗ／Ｖ％カルボシスティンシロップの＋１）１
と安定性（５０’ 、 ３０日）着色度の変化はｐＨ５
，３にやや大きい傾向を示すが、ｐＨ５，８以上では変
化は少なかった。Table 3.5W/V% carbocystine syrup +1)1
and stability (50', 30 days) change in degree of coloration at pH 5
, 3 showed a slightly larger tendency, but there was little change at pH 5, 8 or higher.
残存率は、ｐＨ５，３及びｐＨ７，’ｌにおいてやや低
下した。これらのｐＨ範囲でほぼ安定であるが、望まし
いｐＨ範囲は６．０〜７．５であった。ｐＨ調整剤とし
ては通常用いられるアルカリ剤で良く、最も適するのは
水酸化ナトリウム水溶液であった。The residual rate decreased slightly at pH 5.3 and pH 7.'l. Although it is almost stable in these pH ranges, the desirable pH range was 6.0 to 7.5. As the pH adjuster, a commonly used alkaline agent may be used, and the most suitable one was an aqueous sodium hydroxide solution.
本発明のシロップ剤には、上記甘味剤に加え、安定剤と
して、Ｌ−システイン、ＥＤＴＡ及び亜硫酸水素ナトリ
ウム等を添加することも可能であり、それらの添加量は
０．０１〜０１％であり、カルボシスティンシロップの
安定性を高めることができる。In addition to the above-mentioned sweeteners, stabilizers such as L-cysteine, EDTA, and sodium hydrogen sulfite may be added to the syrup of the present invention, and the amount thereof to be added is 0.01 to 01%. , can increase the stability of carbocystine syrup.
この他、シロップ剤に一般的に添加される保存剤として
、ソルビン酸をその添加量０．０５〜０．２％、望まし
くは０．１Ｗ／Ｖ％、また着色剤としてカラメルをその
添加量０．０２〜０．１％、望ましくはｏ、ｏ６ｗ／ｖ
％及び微量の香料としてフルーツエッセンスを添加して
もよい。In addition, as a preservative commonly added to syrups, sorbic acid is added in an amount of 0.05 to 0.2%, preferably 0.1 W/V%, and caramel is added as a coloring agent in an amount of 0. .02-0.1%, preferably o, o6w/v
Fruit essences may be added as flavoring agents and trace amounts.
［実施例］
以下、実施例により発明具体化の諸態様を説明するが、
かかる例示によって本発明が限定されるものではない。[Example] Hereinafter, various aspects of embodiment of the invention will be explained using Examples.
The present invention is not limited to such examples.
実施例１゜
カルボシスティン５０ｇ及びソルビン酸１．０ｇを精製
水ｅｏｏｍｉに加えて攪拌し、２０Ｗ／Ｖ％水酸化ナト
リウム水溶液５８ｍＭを加えて攪拌溶解した。これに、
Ｄ−ソルビトール４００ｇを加えて攪拌溶解し、２０Ｗ
／Ｖ％水酸化ナトリウム水溶液を加えてｐＨを６．５に
調整した後、カラメル０．６８及び少量のフルーツエッ
センスを加え、精製水を加えて全量ｔｏｏｏｍｐとし、
カルボシスティンシロップ剤を製した。Example 1 50g of carbocystine and 1.0g of sorbic acid were added to purified water eoomi and stirred, and 58mM of 20W/V% sodium hydroxide aqueous solution was added and dissolved with stirring. to this,
Add 400g of D-sorbitol, stir and dissolve, and heat at 20W.
/V% sodium hydroxide aqueous solution was added to adjust the pH to 6.5, then caramel 0.68 and a small amount of fruit essence were added, and purified water was added to bring the total volume to 6.5.
Carbocystine syrup was prepared.
実施例２゜
カルボシスティン１００ｇ及びソルビン酸２．０ｇを精
製水１２００社に加えて攪拌し、２０Ｗ／Ｖ％水酸化ナ
トリウム水溶液１１５ｍＵを加えて攪拌溶解した。これ
に、キシリトール１２００ｇを加えて攪拌溶解し、２０
Ｗ／Ｖ％水酸化ナトリウム水溶液を加えてｐＨを７．０
に調整した後、少量のカラメル及びフルーツエッセンス
を加え、精製水を加えて全量２０００ｎ＋又とし、カル
ボシスティンシロップ剤を製した。Example 2 100 g of carbocystine and 2.0 g of sorbic acid were added to purified water 1200 and stirred, and 115 mU of a 20 W/V% sodium hydroxide aqueous solution was added and dissolved with stirring. Add 1200g of xylitol to this, stir and dissolve,
Add W/V% sodium hydroxide aqueous solution to adjust the pH to 7.0.
After adjusting the mixture to 2,000 N+, a small amount of caramel and fruit essence was added, and purified water was added to make a total amount of 2000 N+ to prepare a carbocystine syrup.
実施例３゜
カルボシスティン１００ｇ及びソルビン酸２．Ｏｇを精
製水１２００ｎｌに加えて攪拌混和し、２０Ｗ／Ｖ％水
酸化ナトリウム水溶液１１５ｍ１を加えて攪拌溶解した
、これに、Ｄ−ソルビトール８００ｇ及びサッカリンナ
トリウム４ｇを加えて攪拌溶解し、２０Ｗ／Ｖ％水酸化
ナトリウム水溶液を加えてｐＨを７．０に調整した後、
少量のカラメル及びフルーツエッセンスを加え、精製水
を加えて全Ｊｉ２０００ｎｌ！とし１、カルボシスティ
ンシロップ剤を製した。Example 3 100 g of carbocystine and sorbic acid 2. Og was added to 1200 nl of purified water and mixed with stirring, and 115 ml of 20 W/V% sodium hydroxide aqueous solution was added and dissolved with stirring. To this, 800 g of D-sorbitol and 4 g of sodium saccharin were added and dissolved with stirring, and 20 W/V% water was added. After adjusting the pH to 7.0 by adding an aqueous sodium oxide solution,
Add a small amount of caramel and fruit essence, add purified water, and the total amount is 2000nl! First, a carbocystine syrup was prepared.
実施例４゜
カルボシスティン５０ｇ及びソルビン酸１ｇを精製水５
００ｍＵに加え、これにｌＯ％水酸化ナトリウム水溶液
１１５ｍ又を加えて溶かす。次にＤ−ゾルビトール４０
０ｇ、亜硫酸水素ナトリウム０．２ｇ及び香料を微量添
加し、攪拌溶解後、１０％水酸化ナトリウム水溶液を用
いてｐ）１６．８に調整し、精製水を加えて全量Ｉ℃と
し、カルボシスティンシロップ剤を製した。Example 4 50g of carbocystine and 1g of sorbic acid were added to 55g of purified water.
00 mU, and 115 mU of 1O% aqueous sodium hydroxide solution is added thereto and dissolved. Next, D-Sorbitol 40
Add 0g of sodium hydrogen sulfite, 0.2g of sodium bisulfite, and a small amount of fragrance, stir and dissolve, adjust to p) 16.8 using a 10% aqueous sodium hydroxide solution, add purified water to bring the total volume to I°C, and prepare carbocystine syrup. A drug was prepared.
実施例５゜
カルボシスティン１０００ｇ及びソルビン酸２０ｇを精
製水１０４１に加えて攪拌し、これに１０％水酸化ナト
リウム水溶液２３０Ｏｎ＋４を加えて攪拌溶解した後、
Ｄ−ソルビトール８０００ｇ 。Example 5 1000 g of carbocystine and 20 g of sorbic acid were added to 1041 of purified water and stirred, and 10% aqueous sodium hydroxide solution 230 On+4 was added thereto and dissolved with stirring.
D-Sorbitol 8000g.
カラメル１２ｇ及び少量の香料を加えて溶解する。１０
％水酸化ナトリウム水溶液を加えてｐＨな６．８に調整
し、精製水を加えて全量２０Ｊ２とし、カルボシスティ
ンシロップ剤を製した。Add 12 g of caramel and a small amount of flavoring and dissolve. 10
% aqueous sodium hydroxide solution was added to adjust the pH to 6.8, and purified water was added to make a total volume of 20J2 to prepare a carbocystine syrup.
以上の各実施例により製造されたカルボシスティンシロ
ップ剤は、着色変化が殆どなく、味覚にも優れた安定性
の高いシロップ剤であった。The carbocystine syrups produced in each of the above examples were highly stable syrups with almost no color change and excellent taste.
［発明の効果］
この発明は、以上説明した様に、カルボシスティンの水
溶液に糖アルコールを加え、ｐＨを調整することにより
、着色変化を抑えた安定性の高いシロップ剤を製するこ
とができた。また、この様にして得られたカルボシステ
ィンシロップ剤は味覚の良い有用性の高いものであった
。[Effects of the Invention] As explained above, in this invention, by adding sugar alcohol to an aqueous solution of carbocystine and adjusting the pH, it was possible to produce a highly stable syrup with suppressed color change. . In addition, the carbocystine syrup thus obtained had a good taste and was highly useful.
Claims (1)
むことを特徴とする医薬用組成物。 ２ カルボシステインの濃度が、少なくとも２Ｗ／Ｖ％
以上である特許請求の範囲第１項の組成物。 ３ 糖アルコールが、Ｄ−ソルビトール並びにキシリト
ールのどちらか一方であるか、又はこれに加えてサッカ
リンナトリウムを加えたものである特許請求の範囲第１
項又は第２項の組成物。 ４ ｐＨ調整剤により、ｐＨを６．０〜７．５に調整し
た特許請求の範囲第１項ないし第３項のいずれかの組成
物。 ５ ２〜１０Ｗ／Ｖ％のカルボシステイン、１０〜７０
Ｗ／Ｖ％の糖アルコール及び０．０５〜０．２Ｗ／Ｖ％
の保存剤を含む特許請求の範囲第１項ないし第４項のい
ずれかの組成物。 ６ 着色剤、香料及び安定化剤を含む特許請求の範囲第
１項ないし第５項のいずれかの組成物。 ７ 保存剤が、ソルビン酸である特許請求の範囲第５項
の組成物。 ８ 着色剤がカラメルである特許請求の範囲第６項の組
成物。 ９ 香料がフルーツエッセンスである特許請求の範囲第
６項の組成物。 １０ 安定化剤が、Ｌ−システイン、ＥＤＴＡ及び亜硫
酸水素ナトリウムのいずれか１つである特許請求の範囲
第６項の組成物。[Scope of Claims] 1. A pharmaceutical composition characterized in that the carbocysteine syrup contains a sugar alcohol. 2 The concentration of carbocysteine is at least 2 W/V%
The composition according to claim 1, which is the above. 3. Claim 1, wherein the sugar alcohol is either D-sorbitol or xylitol, or saccharin sodium is added thereto.
The composition of item 2 or item 2. 4. The composition according to any one of claims 1 to 3, the pH of which is adjusted to 6.0 to 7.5 using a pH adjuster. 5 2-10 W/V% Carbocysteine, 10-70
W/V% sugar alcohol and 0.05-0.2 W/V%
A composition according to any one of claims 1 to 4, comprising a preservative. 6. The composition according to any one of claims 1 to 5, comprising a coloring agent, a fragrance, and a stabilizer. 7. The composition of claim 5, wherein the preservative is sorbic acid. 8. The composition of claim 6, wherein the colorant is caramel. 9. The composition of claim 6, wherein the flavoring agent is a fruit essence. 10. The composition of claim 6, wherein the stabilizer is any one of L-cysteine, EDTA, and sodium bisulfite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30346286A JPH0813737B2 (en) | 1986-12-19 | 1986-12-19 | Syrup |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30346286A JPH0813737B2 (en) | 1986-12-19 | 1986-12-19 | Syrup |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63156719A true JPS63156719A (en) | 1988-06-29 |
| JPH0813737B2 JPH0813737B2 (en) | 1996-02-14 |
Family
ID=17921260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP30346286A Expired - Lifetime JPH0813737B2 (en) | 1986-12-19 | 1986-12-19 | Syrup |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0813737B2 (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2660553A1 (en) * | 1990-04-06 | 1991-10-11 | Rhone Poulenc Sante | Syrup based on carbocisteine having improved stability |
| JPH04288013A (en) * | 1991-03-15 | 1992-10-13 | Kyorin Pharmaceut Co Ltd | Suspended syrup agent |
| JPH0558888A (en) * | 1991-09-06 | 1993-03-09 | Kyorin Pharmaceut Co Ltd | Inhalant |
| JPH0558887A (en) * | 1991-09-06 | 1993-03-09 | Kyorin Pharmaceut Co Ltd | Inhalant |
| WO2002096407A1 (en) * | 2001-05-25 | 2002-12-05 | Ssp Co., Ltd. | Liquid drug preparations |
| JP2004161700A (en) * | 2002-11-14 | 2004-06-10 | Kobayashi Pharmaceut Co Ltd | Composition in which bitterness and odor of cysteines are reduced |
| WO2007097325A1 (en) * | 2006-02-20 | 2007-08-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising oseltamivir phosphate |
| WO2013041810A1 (en) * | 2011-09-22 | 2013-03-28 | Arcadophta | Stable, low-toxicity, sterilizable composition for ophthalmic dying |
| WO2014096497A1 (en) * | 2012-12-19 | 2014-06-26 | Itf Research Pharma, S.L.U. | Liquid carbocisteine formulations having improved properties |
| GR1009513B (en) * | 2017-10-05 | 2019-04-24 | Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. | Drinkable pharmaceutical carbocysteine-containing solutions |
| CN109745301A (en) * | 2017-11-08 | 2019-05-14 | 北京盈科瑞创新药物研究有限公司 | A kind of carbocisteine Neulized inhalation pharmaceutical solutions and preparation method thereof |
-
1986
- 1986-12-19 JP JP30346286A patent/JPH0813737B2/en not_active Expired - Lifetime
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2660553A1 (en) * | 1990-04-06 | 1991-10-11 | Rhone Poulenc Sante | Syrup based on carbocisteine having improved stability |
| JPH04288013A (en) * | 1991-03-15 | 1992-10-13 | Kyorin Pharmaceut Co Ltd | Suspended syrup agent |
| JPH0558888A (en) * | 1991-09-06 | 1993-03-09 | Kyorin Pharmaceut Co Ltd | Inhalant |
| JPH0558887A (en) * | 1991-09-06 | 1993-03-09 | Kyorin Pharmaceut Co Ltd | Inhalant |
| US7592372B2 (en) | 2001-05-25 | 2009-09-22 | Hisamitsu Pharmaceutical Co., Inc. | Liquid drug preparations |
| WO2002096407A1 (en) * | 2001-05-25 | 2002-12-05 | Ssp Co., Ltd. | Liquid drug preparations |
| JP4501023B2 (en) * | 2002-11-14 | 2010-07-14 | 小林製薬株式会社 | Composition with reduced bitterness and odor of cysteines |
| JP2004161700A (en) * | 2002-11-14 | 2004-06-10 | Kobayashi Pharmaceut Co Ltd | Composition in which bitterness and odor of cysteines are reduced |
| WO2007097325A1 (en) * | 2006-02-20 | 2007-08-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising oseltamivir phosphate |
| US9012499B2 (en) | 2006-02-20 | 2015-04-21 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition comprising oseltamivir phosphate |
| WO2013041810A1 (en) * | 2011-09-22 | 2013-03-28 | Arcadophta | Stable, low-toxicity, sterilizable composition for ophthalmic dying |
| FR2980363A1 (en) * | 2011-09-22 | 2013-03-29 | Arcadophta | COMPOSITION WITH REDUCED TOXICITY OF AT LEAST ONE STABLE AND STERILIZABLE COLORANT |
| WO2014096497A1 (en) * | 2012-12-19 | 2014-06-26 | Itf Research Pharma, S.L.U. | Liquid carbocisteine formulations having improved properties |
| GR1009513B (en) * | 2017-10-05 | 2019-04-24 | Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. | Drinkable pharmaceutical carbocysteine-containing solutions |
| CN109745301A (en) * | 2017-11-08 | 2019-05-14 | 北京盈科瑞创新药物研究有限公司 | A kind of carbocisteine Neulized inhalation pharmaceutical solutions and preparation method thereof |
| WO2019091082A1 (en) * | 2017-11-08 | 2019-05-16 | 北京盈科瑞创新药物研究有限公司 | Solution preparation for aerosol inhalation of carbocisteine, and preparation method therefor |
| JP2021502398A (en) * | 2017-11-08 | 2021-01-28 | ベイジン インクリース イノベーション ドラッグ リサーチ カンパニー リミテッド | Carbocisteine aerosol inhalation solution preparation and its manufacturing method |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0813737B2 (en) | 1996-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3113026B2 (en) | Concentrate composition | |
| EP0100157B1 (en) | Nystatin pastille formulation | |
| JPS6351325A (en) | Stabilized liquid analgesic composition | |
| DK162573B (en) | SYNERGISTIC SWEET PREPARATION AND ITS USE | |
| CN109893502B (en) | Tofacitinib citrate composition and preparation method thereof | |
| JP4051717B2 (en) | Biotin-containing oral solution | |
| JPS63156719A (en) | Syrup | |
| JPH022326A (en) | Sweetener having heterocyclic group | |
| JP3805646B2 (en) | Pharmaceutical solution | |
| EP0792589A1 (en) | Use of erythritol in soft drinks | |
| PL195674B1 (en) | Oral solution of prucalopride | |
| KR100254107B1 (en) | Stable liquid preparation of complex vitamin for internal use | |
| JP4206506B2 (en) | Solution containing vitamin B1 | |
| JP4013267B2 (en) | Oral solution | |
| JPH11106354A (en) | Pharmaceutical bitterness-masked oral agent | |
| JPH0827034A (en) | Liquid agent for internal use containing erythritol | |
| US5698562A (en) | Palatable trimethoprim oral solution | |
| HU211912A9 (en) | Syrup containing n-acetyl-cysteine | |
| JPH10265369A (en) | Liquid agent for internal use having improved taste | |
| JPH03502161A (en) | salt substitute | |
| JPH11139970A (en) | Oral solution | |
| RU2002111689A (en) | COMPOSITIONS OF HIGH-INTENSE SWEETS HAVING AN IMPROVED SWEET, TASTE MODIFIER AND THEIR APPLICATION | |
| JP3288406B2 (en) | Novel beverage composition containing dipeptide sweetener, saccharin salt and hydrated colloidal polysaccharide | |
| GR1009069B (en) | Drinkable pharmaceutical high-concentration solutions containing hydrochloric ranitidine | |
| JPH10120559A (en) | Internal liquid medicine containing taurine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |